Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 5/20 | 0.45 |
| ▸ | HRH1 | P35367 | 5/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17313870 | 1.00 | DPP7 (0.50) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL17313872 | 0.96 | DPP7 (0.49) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL17313869 | 0.96 | DPP7 (0.49) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL17313867 | 0.96 | DPP7 (0.49) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL17313879 | 0.93 | DPP7 (0.44) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL17313878 | 0.93 | DPP7 (0.44) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL26040761 | 0.90 | HRH2 (0.49) | DPP7DPP8DPP9DPP4GNAI3 | |
| SCHEMBL17313857 | 0.89 | DPP7 (0.43) | DPP7DPP8DPP9DPP4CHRM3 | |
| SCHEMBL17313855 | 0.89 | DPP7 (0.43) | DPP7DPP8DPP9DPP4CHRM3 | |
| SCHEMBL17313858 | 0.89 | DPP7 (0.43) | DPP7DPP8DPP9DPP4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035886-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2017-02-09 | — | — | US | claimed |
| US-20150353514-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2015-12-10 | — | — | US | claimed |
| US-9822083-B2 | Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof | BIOCELLCHALLENGE (FR) | 2017-11-21 | — | — | US | disclosed |
| US-20170035886-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2017-02-09 | — | — | US | disclosed |
| US-20150353514-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | BIOCELLCHALLENGE (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353514-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | ABCB4, SLC47A2, SLC47A1 | DPP7 1584/4885DPP8 2097/4885DPP9 1411/4885 |
| US-20170035886-A1 | AMPHIPHILIC DERIVATIVES OF TRIAZAMACROCYCLIC COMPOUNDS, PRODUCTS AND COMPOSITIONS INCLUDING SAME, AND SYNTHESIS METHODS AND USES THEREOF | ABCB4, SLC47A2, SLC47A1 | DPP7 1584/4885DPP8 2097/4885DPP9 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.